FDA DEVICE FACTS
LIAISON® XL MUREX Anti-HDV (318260); LIA
DiaSorin, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The LIAISON XL MUREX Anti-HDV assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative detection of antibodies to the hepatitis D virus (anti-HDV) in adult human serum, lithium, sodium heparin, and K2-EDTA plasma. The assay is intended as an aid in the presumptive diagnosis of HDV infection in individuals who are HBsAg positive and at risk for HDV infection. Assay results, in conjunction with other laboratory results and clinical information, may be used to provide evidence of infection with HDV. This test does not determine the state of infection or associated disease. The test must be performed on the LIAISON XL Analyzer. The LIAISON XL MUREX Control Anti-HDV (negative and positive) are intended for use as assayed quality control samples to monitor the performance and reliability of LIAISON XL MUREX Anti-HDV assay. The performance characteristics of LIAISON XL MUREX Anti-HDV controls have not been established for any other assays or instrument platforms different from LIAISON XL Analyzer.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。